Develops antibodies for inflammatory bowel and rheumatic diseases.
Dec 2025Revenue $0.00/yrExpenses $210M/yr
No trendCash runway ≈ 5.5 years from Jun 2026
Figures by year
When will Spyre Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $0.00 and expenses $210M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $210M | −$210M |
| Dec 2024 | $0.00 | $209M | −$209M |
| Dec 2023 | $886K | $243M | −$242M |
| Dec 2022 | $2.33M | $87.1M | −$84.8M |
| Dec 2021 | $18.7M | $84.4M | −$65.6M |
| Dec 2020 | $0.00 | $81.5M | −$81.5M |
| Dec 2019 | $0.00 | $80.3M | −$80.3M |
| Dec 2018 | $3.89M | $49.4M | −$45.5M |
| Dec 2017 | $5.21M | $32.9M | −$27.7M |
| Dec 2016 | $4.63M | $26.5M | −$21.9M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.